Novavax (NASDAQ:NVAX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Novavax (NASDAQ:NVAX) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

Several other equities analysts have also recently commented on the stock. BTIG Research restated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research report on Thursday, June 11th. Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a research note on Tuesday, August 4th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Novavax currently has an average rating of “Hold” and an average price target of $14.00.

Novavax Stock Performance

Shares of NASDAQ NVAX opened at $9.42 on Friday. Novavax has a 52 week low of $6.20 and a 52 week high of $11.97. The stock has a market capitalization of $1.55 billion, a P/E ratio of -6.20 and a beta of 2.45. The stock’s fifty day moving average is $8.62 and its 200 day moving average is $9.02.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. The business had revenue of $56.70 million during the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. Novavax’s revenue was down 76.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 earnings per share. Equities research analysts forecast that Novavax will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC bought a new position in shares of Novavax in the second quarter worth about $42,000. Squarepoint Ops LLC bought a new stake in shares of Novavax during the 2nd quarter valued at approximately $1,258,000. Allworth Financial LP grew its holdings in shares of Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 3,244 shares during the last quarter. Corient Private Wealth LP acquired a new position in Novavax during the 2nd quarter worth approximately $155,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Novavax during the 2nd quarter worth approximately $739,000. Institutional investors own 53.04% of the company’s stock.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax outperformed the broader market in the most recent session, according to Zacks. The article highlights the stock’s relative strength, although it does not identify a new fundamental catalyst. Novavax (NVAX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Novavax presented at Citigroup’s Biopharma Back to School Summit, giving investors an opportunity to assess management’s strategy, pipeline and commercial outlook. No specific new deal, clinical update or financial guidance change was provided in the available summary. Novavax Presents at Citigroup’s Biopharma Back to School Summit 2026
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio for both periods. Because the figures appear anomalous, they do not provide a reliable indication of short-covering pressure or bearish positioning.
• Negative Sentiment: One market commentary piece included Novavax among small-cap stocks viewed skeptically, emphasizing the company’s volatility and risks associated with smaller biotechnology companies. 3 Russell 2000 Stocks We’re Skeptical Of
• Negative Sentiment: Analysts’ average rating on Novavax remains “Hold,” suggesting limited conviction that the stock will deliver substantial near-term gains. Novavax Receives Average Rating of Hold from Analysts

About Novavax

Novavax, Inc is a biotechnology company focused on discovering, developing and commercializing vaccines for infectious diseases. The company’s vaccine platform uses recombinant nanoparticle technology and Matrix-M, its proprietary saponin-based adjuvant, which is designed to enhance and broaden immune responses.

Novavax’s primary commercial product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in multiple markets. The vaccine has also been marketed as Covovax through partnerships in certain countries.